ATE482972T1 - Tgf-beta1-bindende und geträgerte peptide - Google Patents

Tgf-beta1-bindende und geträgerte peptide

Info

Publication number
ATE482972T1
ATE482972T1 AT04810432T AT04810432T ATE482972T1 AT E482972 T1 ATE482972 T1 AT E482972T1 AT 04810432 T AT04810432 T AT 04810432T AT 04810432 T AT04810432 T AT 04810432T AT E482972 T1 ATE482972 T1 AT E482972T1
Authority
AT
Austria
Prior art keywords
peptides
supported
tgf
preferred embodiments
supported peptides
Prior art date
Application number
AT04810432T
Other languages
English (en)
Inventor
Anthony Day
David A Estell
Christopher Murray
Scott Power
Beverly Turnquest
Original Assignee
Danisco Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danisco Us Inc filed Critical Danisco Us Inc
Application granted granted Critical
Publication of ATE482972T1 publication Critical patent/ATE482972T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
AT04810432T 2003-11-06 2004-11-06 Tgf-beta1-bindende und geträgerte peptide ATE482972T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US51815403P 2003-11-06 2003-11-06
US52040303P 2003-11-13 2003-11-13
US53118903P 2003-12-19 2003-12-19
US53095403P 2003-12-19 2003-12-19
US53120703P 2003-12-19 2003-12-19
PCT/US2004/036979 WO2005046710A2 (en) 2003-11-06 2004-11-06 Tgf-beta binding and supported peptides

Publications (1)

Publication Number Publication Date
ATE482972T1 true ATE482972T1 (de) 2010-10-15

Family

ID=34596198

Family Applications (4)

Application Number Title Priority Date Filing Date
AT04810431T ATE530560T1 (de) 2003-11-06 2004-11-06 Vegf bindende und geträgerte peptide zur behandlung von hautkrankheiten
AT04800809T ATE513917T1 (de) 2003-11-06 2004-11-06 Bakterielle expression von proteaseinhibitoren und varianten davon
AT04810432T ATE482972T1 (de) 2003-11-06 2004-11-06 Tgf-beta1-bindende und geträgerte peptide
AT04818640T ATE486087T1 (de) 2003-11-06 2004-11-06 Fgf-5-bindende und geträgerte peptide

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT04810431T ATE530560T1 (de) 2003-11-06 2004-11-06 Vegf bindende und geträgerte peptide zur behandlung von hautkrankheiten
AT04800809T ATE513917T1 (de) 2003-11-06 2004-11-06 Bakterielle expression von proteaseinhibitoren und varianten davon

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04818640T ATE486087T1 (de) 2003-11-06 2004-11-06 Fgf-5-bindende und geträgerte peptide

Country Status (9)

Country Link
US (8) US20080113917A1 (de)
EP (4) EP1680507B1 (de)
JP (2) JP4843497B2 (de)
AT (4) ATE530560T1 (de)
CA (1) CA2544820C (de)
DE (2) DE602004029393D1 (de)
DK (2) DK1692158T3 (de)
ES (1) ES2375360T3 (de)
WO (4) WO2005046709A2 (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279564B2 (en) * 2003-11-06 2007-10-09 Genencor International, Inc. Expression in filamentous fungi of protease inhibitors and variants thereof
US20080113917A1 (en) * 2003-11-06 2008-05-15 Day Anthony G Tgfbeta Supported and Binding Peptides
WO2006044650A2 (en) * 2004-10-15 2006-04-27 Genencor International, Inc. Competitive differential screening
BRPI0613548A2 (pt) * 2005-05-05 2011-01-18 Genencor Int composições de cuidado pessoal e métodos para seu uso
ATE477272T1 (de) 2005-06-10 2010-08-15 Medical Res Council Verwendung von stefin a als gerüstprotein
EP1902066A4 (de) * 2005-07-13 2009-01-07 Amgen Mountain View Inc Il-6-bindende proteine
GB0601684D0 (en) * 2006-01-27 2006-03-08 Reckitt Benckiser Uk Ltd Composition, process for preparation and method of use
WO2007092465A2 (en) * 2006-02-07 2007-08-16 Dyao Pharmaceutical Corporation Topical delivery compositions
ES2427856T3 (es) * 2006-09-16 2013-11-04 Soy Labs Llc Utilización de péptido de soja (lunasina) para reducir la tasa de colesterol total y LDL
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US20080090745A1 (en) * 2006-10-13 2008-04-17 Fox Bryan P Expression of Streptomyces subtilism inhibitor (SSI) proteins in Bacillus and Streptomyces sp.
CA2672609C (en) * 2006-12-18 2015-11-24 Danisco Us Inc., Genencor Division Laccase mediators and methods of use
JP2010512787A (ja) * 2006-12-21 2010-04-30 ダニスコ・ユーエス・インク、ジェネンコー・ディビジョン バシルス（Ｂａｃｉｌｌｕｓ）種１９５のアルファ‐アミラーゼポリペプチドの組成物と使用。
CN101778940B (zh) * 2007-06-06 2017-04-05 丹尼斯科美国公司 改进多种蛋白质性质的方法
US20090048136A1 (en) * 2007-08-15 2009-02-19 Mcdonald Hugh C Kappa-carrageenase and kappa-carrageenase-containing compositions
WO2009058518A1 (en) * 2007-10-31 2009-05-07 Danisco Us Inc., Genencor Division Use and production of neutral metallproteases in a serine protease-free background
BRPI0818273A2 (pt) * 2007-11-01 2014-10-14 Danisco Us Inc Sequências sinalizadoras e chaperonas coexpressas para aprimoramento de produção de proteína em uma célula hospedeira.
GB0722332D0 (en) * 2007-11-14 2007-12-27 Reckitt Benckiser Uk Ltd Personal care article
WO2009096916A1 (en) * 2008-01-29 2009-08-06 Genencor International, Inc. Expression of streptomyces subtilisin inhibitor (ssi) proteins in bacillus and streptomyces sp.
CA2713582C (en) 2008-02-04 2017-02-21 Danisco Us Inc. Ts23 alpha-amylase variants with altered properties
US7803902B2 (en) 2008-10-15 2010-09-28 Danisco Us Inc. Modified variant bowman birk protease inhibitors
CA2740197A1 (en) * 2008-10-15 2010-04-22 Danisco Us Inc. Modified variant bowman birk protease inhibitors
US7772181B2 (en) 2008-10-15 2010-08-10 Danisco Us Inc. Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
WO2010104675A1 (en) 2009-03-10 2010-09-16 Danisco Us Inc. Bacillus megaterium strain dsm90-related alpha-amylases, and methods of use, thereof
US20100247693A1 (en) * 2009-03-24 2010-09-30 Marini Jan L Cosmetic formulation to treat rosacea telangiectasia
CN102388131B (zh) 2009-04-08 2014-04-30 丹尼斯科美国公司 盐单胞菌属菌株WDG195相关α-淀粉酶及其使用方法
WO2010123754A1 (en) 2009-04-24 2010-10-28 Danisco Us Inc. Proteases with modified pro regions
US8388991B2 (en) * 2009-05-01 2013-03-05 Chattem, Inc. Moisturizing antimicrobial composition
AR076941A1 (es) 2009-06-11 2011-07-20 Danisco Us Inc Cepa de bacillus para una mayor produccion de proteina
US20110052676A1 (en) * 2009-09-01 2011-03-03 James Vincent Gruber Composition For Delaying Cellular Senescence
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
GB0921001D0 (en) * 2009-11-30 2010-01-13 Aqua Bio Technology Asa Products and uses
US8728790B2 (en) 2009-12-09 2014-05-20 Danisco Us Inc. Compositions and methods comprising protease variants
EP2512501A4 (de) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc Haarwuchsverfahren unter verwendung extrazellulärer fgfr3-domänen
EP2519245A4 (de) * 2009-12-30 2013-08-28 Solae Llc Aus einem sojaverarbeitungsstrom isolierte gereinigte kunitz-trypsin-hemmerproteine
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
SG184345A1 (en) 2010-03-31 2012-11-29 Agency Science Tech & Res Amphiphilic linear peptide/peptoid and hydrogel comprising the same
US8999916B2 (en) 2010-03-31 2015-04-07 Agency For Science, Technology And Research Crosslinked peptide hydrogels
US9687591B2 (en) 2010-03-31 2017-06-27 Agency For Science, Technology And Research Building stratified biomimetic tissues and organs using crosslinked ultrashort peptide hydrogel membranes
WO2011130222A2 (en) 2010-04-15 2011-10-20 Danisco Us Inc. Compositions and methods comprising variant proteases
CN105925555B (zh) 2010-05-06 2020-12-22 丹尼斯科美国公司 包含枯草杆菌蛋白酶变体的组合物和方法
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
EP2705146B1 (de) 2011-05-05 2018-11-07 Danisco US Inc. Zusammensetzungen und verfahren mit serinproteasevarianten
JP5933688B2 (ja) 2011-05-05 2016-06-15 ザ プロクター アンド ギャンブル カンパニー セリンプロテアーゼ変異体を含む組成物及び方法
AR087745A1 (es) 2011-08-31 2014-04-16 Danisco Us Inc Composiciones y metodos que comprenden una variante de enzima lipolitica
CN104024407A (zh) 2011-12-22 2014-09-03 丹尼斯科美国公司 包含脂解酶变体的组合物和方法
US9120841B2 (en) 2012-09-28 2015-09-01 Agency For Science, Technology And Research Amphiphilic linear peptidepeptoid and hydrogel comprising the same
CA2887898A1 (en) 2012-10-12 2014-04-17 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
KR20150082502A (ko) 2012-11-05 2015-07-15 다니스코 유에스 인크. 써몰리신 프로테아제 변이체를 포함하는 조성물 및 방법
WO2014100018A1 (en) 2012-12-19 2014-06-26 Danisco Us Inc. Novel mannanase, compositions and methods of use thereof
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
WO2014194117A2 (en) 2013-05-29 2014-12-04 Danisco Us Inc. Novel metalloproteases
CN105492603B (zh) 2013-05-29 2022-06-03 丹尼斯科美国公司 新型金属蛋白酶
WO2014194032A1 (en) 2013-05-29 2014-12-04 Danisco Us Inc. Novel metalloproteases
EP3260538B1 (de) 2013-05-29 2021-04-14 Danisco US Inc. Neuartige metalloproteasen
WO2015010009A2 (en) 2013-07-19 2015-01-22 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
EP3653707A1 (de) 2013-09-12 2020-05-20 Danisco US Inc. Zusammensetzungen und verfahren mit lg12-klade-protease-varianten
RU2016117978A (ru) * 2013-10-11 2017-11-17 Дженентек, Инк. Ингибиторы nsp4 и способы их применения
JP2016535770A (ja) 2013-11-01 2016-11-17 スフェリウム バイオメッド エス．エル． 治療用及び美容用物質を経皮送達するための封入体
EP3553173B1 (de) 2013-12-13 2021-05-19 Danisco US Inc. Serinproteasen des bazillus gibsonii-clade
ES2723948T3 (es) 2013-12-13 2019-09-04 Danisco Us Inc Serina proteasas procedentes de especies de Bacillus
US9737592B1 (en) * 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
EP4155398A1 (de) 2014-03-21 2023-03-29 Danisco US Inc. Serinproteasen aus einer bacillus-spezies
DK3207129T3 (da) 2014-10-17 2020-02-24 Danisco Us Inc Serinproteaser af bacillus-arten
EP3212662B1 (de) 2014-10-27 2020-04-08 Danisco US Inc. Serinproteasen
CN107148472A (zh) 2014-10-27 2017-09-08 丹尼斯科美国公司 芽孢杆菌属物种的丝氨酸蛋白酶
EP3212781B1 (de) 2014-10-27 2019-09-18 Danisco US Inc. Serinproteasen
EP3212783A1 (de) 2014-10-27 2017-09-06 Danisco US Inc. Serinproteasen
EP3212782B1 (de) 2014-10-27 2019-04-17 Danisco US Inc. Serinproteasen
DK3268471T3 (da) 2015-03-12 2019-12-02 Danisco Us Inc Sammensætninger og fremgangsmåder omfattende lg12-clade-proteasevarianter
US20180112204A1 (en) 2015-05-13 2018-04-26 Danisco Us Inc. AprL-CLADE PROTEASE VARIANTS AND USES THEREOF
EP4234693A3 (de) 2015-06-17 2023-11-01 Danisco US Inc Bacillus-gibboni-clade-serin-proteasen
MX2017016499A (es) 2015-06-17 2018-03-12 Danisco Us Inc Proteasas con regiones de propeptido modificadas.
CN107022432A (zh) * 2016-01-29 2017-08-08 高露洁-棕榄公司 清洁组合物
EP3845642B1 (de) 2016-05-05 2023-08-09 Danisco US Inc. Proteasevarianten und verwendungen davon
MX2018014768A (es) 2016-05-31 2019-03-06 Danisco Us Inc Variantes de proteasa y sus usos.
EP4151726A1 (de) 2016-06-17 2023-03-22 Danisco US Inc Proteasevarianten und verwendungen davon
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018118950A1 (en) 2016-12-21 2018-06-28 Danisco Us Inc. Bacillus gibsonii-clade serine proteases
CN110312795A (zh) 2016-12-21 2019-10-08 丹尼斯科美国公司 蛋白酶变体及其用途
US11298391B1 (en) * 2017-04-27 2022-04-12 Lorenol Laboratories, Inc. Topical skin health improvement compositions and administrations thereof
US20200354708A1 (en) 2017-11-29 2020-11-12 Danisco Us Inc. Subtilisin variants having improved stability
WO2019245704A1 (en) 2018-06-19 2019-12-26 Danisco Us Inc Subtilisin variants
US20210363470A1 (en) 2018-06-19 2021-11-25 Danisco Us Inc Subtilisin variants
WO2020046613A1 (en) 2018-08-30 2020-03-05 Danisco Us Inc Compositions comprising a lipolytic enzyme variant and methods of use thereof
EP3875591A4 (de) * 2018-10-31 2022-09-21 Qingdao Vland Biotech Group Co. Ltd. Verfahren zur herstellung eines waschenzyms mit proteaseresistenz
US20230028935A1 (en) 2018-11-28 2023-01-26 Danisco Us Inc Subtilisin variants having improved stability
US20220220419A1 (en) 2019-05-24 2022-07-14 Danisco Us Inc Subtilisin variants and methods of use
CN112062828B (zh) * 2019-06-10 2022-04-29 温州医科大学 Fgf-5多肽抑制剂及其生发应用
US20230049452A1 (en) 2020-01-13 2023-02-16 Danisco Us Inc Compositions comprising a lipolytic enzyme variant and methods of use thereof
WO2022047149A1 (en) 2020-08-27 2022-03-03 Danisco Us Inc Enzymes and enzyme compositions for cleaning
CN113307857B (zh) * 2021-01-14 2022-11-01 艾时斌 从表皮生长因子、凝集素和Tat蛋白衍生的支架蛋白
WO2023278297A1 (en) 2021-06-30 2023-01-05 Danisco Us Inc Variant lipases and uses thereof
WO2023034486A2 (en) 2021-09-03 2023-03-09 Danisco Us Inc. Laundry compositions for cleaning
US20230365897A1 (en) 2021-12-16 2023-11-16 The Procter & Gamble Company Fabric and home care composition including a protease
WO2023114939A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
WO2023114932A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
WO2023114936A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
WO2023114795A1 (en) 2021-12-16 2023-06-22 The Procter & Gamble Company Automatic dishwashing composition comprising a protease
WO2023168234A1 (en) 2022-03-01 2023-09-07 Danisco Us Inc. Enzymes and enzyme compositions for cleaning
WO2024050346A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Detergent compositions and methods related thereto
WO2024050343A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Subtilisin variants and methods related thereto

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755560A (en) * 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
US3929678A (en) * 1974-08-01 1975-12-30 Procter & Gamble Detergent composition having enhanced particulate soil removal performance
JPS51125468A (en) * 1975-03-27 1976-11-01 Sanyo Chem Ind Ltd Method of preparing resins of high water absorbency
US4152416A (en) * 1976-09-17 1979-05-01 Marra Dorothea C Aerosol antiperspirant compositions delivering astringent salt with low mistiness and dustiness
US4421769A (en) * 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
FI69503C (fi) * 1984-03-13 1986-02-10 Neste Oy Ytbelagd bergsbehaollare eller tunnel
US5411873A (en) * 1984-05-29 1995-05-02 Genencor, Inc. Process for producing heterologous polypeptides
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5679543A (en) * 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US4937370A (en) * 1987-06-02 1990-06-26 The Procter & Gamble Company Novel chromophores, sunscreen compositions and methods for preventing sunburn
US4999186A (en) * 1986-06-27 1991-03-12 The Procter & Gamble Company Novel sunscreen agents, sunscreen compositions and methods for preventing sunburn
US5322770A (en) * 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
WO1988002025A1 (en) * 1986-09-17 1988-03-24 Sri International Expression vectors for bacilli
US5087372A (en) * 1989-03-24 1992-02-11 Asahi Kasei Kogyo Kabushiki Kaisha Method for removing heavy metal ions from contaminated water and a porous membrane usable therefor
US5011681A (en) * 1989-10-11 1991-04-30 Richardson-Vicks, Inc. Facial cleansing compositions
US5073371A (en) * 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5073372A (en) * 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5436228A (en) * 1990-12-12 1995-07-25 Postlethwaite; Arnold E. Chemotactic wound healing peptides
US5429950A (en) * 1992-03-30 1995-07-04 Genencor International, Inc. Heterologous gene expression in bacillus subtilis: fusion approach
GB9415421D0 (en) 1994-07-30 1994-09-21 Procter & Gamble Cosmetic compositions and processes for manufacture thereof
JPH10510272A (ja) 1994-11-28 1998-10-06 ザ、プロクター、エンド、ギャンブル、カンパニー 皮膚コンディショニング剤として増粘型ポリオールカルボン酸エステルを含む局所用肌荒れ防止用組成物
AR001732A1 (es) * 1996-03-12 1997-11-26 Genencor Int Celulasa alcalina novedosa y método para producirla
WO1997038708A1 (en) * 1996-04-18 1997-10-23 The General Hospital Corporation Modulating epithelial-mesenchymal interactions
US5827508A (en) * 1996-09-27 1998-10-27 The Procter & Gamble Company Stable photoprotective compositions
US5976838A (en) * 1996-12-18 1999-11-02 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
CZ181199A3 (cs) 1996-11-22 1999-10-13 The Procter & Gamble Company Kosmetický přípravek, který je vhodný pro lokální aplikaci na pokožku nebo vlasy
DE19735587B4 (de) * 1997-08-16 2012-03-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
EA003637B1 (ru) * 1998-07-20 2003-08-28 Инокселл А/С Новые способы идентификации биомолекул лигандов и мишеней
US5935556A (en) * 1998-07-30 1999-08-10 The Procter & Gamble Company Sunscreen compositions
US5989528A (en) 1998-07-30 1999-11-23 The Procter & Gamble Company Sunscreen compositions
JP3855042B2 (ja) * 1998-09-22 2006-12-06 独立行政法人産業技術総合研究所 毛髪の鑑別法
US5968485A (en) * 1998-10-16 1999-10-19 The Procter & Gamble Company UV protection compositions
US5972316A (en) * 1998-10-16 1999-10-26 The Procter & Gamble Company UV protection compositions
WO2000024371A1 (en) 1998-10-23 2000-05-04 The Procter & Gamble Company Skin care compositions
GB9825854D0 (en) * 1998-11-25 1999-01-20 Univ Bristol Peptide
JP3106191B1 (ja) * 1999-03-30 2000-11-06 工業技術院長 Ｆｇｆ−５の生理的機能制御ペプチド及び該ペプチドを含有する医薬組成物
US7090973B1 (en) * 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
US20100293669A2 (en) * 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US6872563B1 (en) * 1999-10-05 2005-03-29 President And Fellows Of Harvard College Compositions and methods for production of disulfide bond containing proteins in host cells
WO2001072957A2 (en) * 2000-03-31 2001-10-04 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
US20020098524A1 (en) * 2000-04-14 2002-07-25 Murray Christopher J. Methods for selective targeting
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US6822082B2 (en) * 2000-06-30 2004-11-23 Zymogenetics, Inc. Polynucleotides for mammalian secreted protein, Z1055G2P
US6537968B1 (en) * 2000-07-24 2003-03-25 Alphamed Pharmaceuticals Corp Treatment of lupus erythematosus
EP1341912B1 (de) * 2000-12-13 2009-05-20 Anaphore, Inc. Methode zur identifikation und isolation von peptide die andere moleküle binden aus kombinatorische proteinbibliotheken mit einer c-typ lectin-ähnlichen domäne als gerüststruktur
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20070020625A1 (en) * 2001-02-07 2007-01-25 Eric Duchaud Sequence of the photorhabdus luminescens strain tt01 genome and uses
US7556939B2 (en) * 2003-02-11 2009-07-07 Institut Pasteur Identification and characterization of racemases, definition of protein signatures, and a test for detecting D-amino acid and for screening molecules capable of inhibiting the activity of racemase, especially proline racemase
US7279564B2 (en) * 2003-11-06 2007-10-09 Genencor International, Inc. Expression in filamentous fungi of protease inhibitors and variants thereof
US20080113917A1 (en) * 2003-11-06 2008-05-15 Day Anthony G Tgfbeta Supported and Binding Peptides
US7319142B1 (en) * 2004-08-31 2008-01-15 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus and uses thereof
US7803902B2 (en) * 2008-10-15 2010-09-28 Danisco Us Inc. Modified variant bowman birk protease inhibitors
US7772181B2 (en) * 2008-10-15 2010-08-10 Danisco Us Inc. Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors

Also Published As

Publication number Publication date
DK1680507T3 (da) 2011-10-10
EP1692159A2 (de) 2006-08-23
ATE486087T1 (de) 2010-11-15
US20080113917A1 (en) 2008-05-15
DK1692158T3 (da) 2012-02-06
EP1680507B1 (de) 2011-06-22
EP1692158A2 (de) 2006-08-23
EP1680507A2 (de) 2006-07-19
JP5728329B2 (ja) 2015-06-03
CA2544820C (en) 2014-02-18
WO2005047314A2 (en) 2005-05-26
US20050203026A1 (en) 2005-09-15
US7413877B2 (en) 2008-08-19
CA2544820A1 (en) 2005-05-26
ATE530560T1 (de) 2011-11-15
EP1692160A2 (de) 2006-08-23
US7485618B2 (en) 2009-02-03
EP1692158B1 (de) 2011-10-26
WO2005047511A2 (en) 2005-05-26
US20050202535A1 (en) 2005-09-15
DE602004029393D1 (de) 2010-11-11
WO2005046710A3 (en) 2005-11-24
DE602004029812D1 (de) 2010-12-09
EP1692160B1 (de) 2010-10-27
JP2012024091A (ja) 2012-02-09
US20110230405A1 (en) 2011-09-22
US20080269139A1 (en) 2008-10-30
WO2005046709A3 (en) 2005-11-24
US20050238607A1 (en) 2005-10-27
JP2008500805A (ja) 2008-01-17
WO2005046709A2 (en) 2005-05-26
ATE513917T1 (de) 2011-07-15
US7696173B2 (en) 2010-04-13
US7524816B2 (en) 2009-04-28
EP1692159B1 (de) 2010-09-29
WO2005046710A2 (en) 2005-05-26
WO2005047511A3 (en) 2005-11-24
US20090111160A1 (en) 2009-04-30
JP4843497B2 (ja) 2011-12-21
US20130065829A1 (en) 2013-03-14
ES2375360T3 (es) 2012-02-29
WO2005047314A3 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
ATE482972T1 (de) Tgf-beta1-bindende und geträgerte peptide
WO2006121610A3 (en) Personal care compositions and methods for their use
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
ATE542920T1 (de) Modifiziertes menschliches wachstumshormon
CY1105616T1 (el) ΠΕΠΤΙΔΙΑ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TGFβ1
DE602004011770D1 (de) Fusionsproteine
EA200701448A1 (ru) Специфически связывающаяся с крипто-антигеном человека молекула (варианты), композиция на ее основе (варианты), способ получения молекулы, способ лечения посредством молекулы (варианты) и способ ингибирования крипто-экспрессии в клетке больного
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
NO20051685L (no) In vitro peptidekspresjonsbibliotek
DE602004019965D1 (de) Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
ATE382364T1 (de) Von igf-bindungsprotein stammendes peptid
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine
EA200801180A1 (ru) Селективные пептидные агонисты рецептора vpac2
CY1111285T1 (el) Θεραπεια αυτοανοσων ασθενειων
ATE466080T1 (de) Formulierungen und verfahren zum denaturieren von proteinen
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
ATE363531T1 (de) Claudin polypeptide
WO2004002418A3 (en) Compositions and methods comprising protein activated receptor antagonists
DE602004014145D1 (de) Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen
WO2003087138A3 (en) Methods for identifying polypeptide factors interacting with rna
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
DE602004015142D1 (de) Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties